Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of kidney cancer. Given the sustained response to ICIs in some patients after treatment discontinuation, intermittent dosing may minimize treatment toxicities and costs. Determining an optimal treatment strategy relies on personalized approaches.
- Financial burden
- Immune checkpoint inhibitors
- Immune-related adverse events
- Intermittent dosing
- Metastatic renal cell carcinoma
- Treatment duration
ASJC Scopus subject areas